Expression	O
of	O
thymidylate	O
synthase	O
and	O
dihydropyrimidine	O
dehydrogenase	O
in	O
primary	B-Cancer
oral	I-Cancer
squamous	I-Cancer
cell	I-Cancer
carcinoma	I-Cancer
and	O
corresponding	O
metastases	B-Cancer
in	O
cervical	B-Multi-tissue_structure
lymph	I-Multi-tissue_structure
nodes	I-Multi-tissue_structure
:	O
association	O
with	O
the	O
metastasis	O
suppressor	O
CD82	O
.	O

Thymidylate	O
synthase	O
(	O
TS	O
)	O
and	O
dihydropyrimidine	O
dehydrogenase	O
(	O
DPD	O
)	O
are	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
metabolizing	O
enzymes	O
and	O
are	O
involved	O
in	O
the	O
sensitivity	O
of	O
carcinoma	B-Cancer
patients	O
to	O
5	O
-	O
FU	O
.	O

Although	O
5	O
-	O
FU	O
is	O
often	O
used	O
for	O
the	O
treatment	O
of	O
oral	B-Cancer
carcinoma	I-Cancer
,	O
there	O
has	O
not	O
been	O
any	O
investigation	O
into	O
the	O
expression	O
of	O
these	O
enzymes	O
in	O
metastatic	B-Multi-tissue_structure
lymph	I-Multi-tissue_structure
nodes	I-Multi-tissue_structure
or	O
of	O
their	O
roles	O
in	O
the	O
effectiveness	O
of	O
5	O
-	O
FU	O
in	O
treating	O
lymph	B-Cancer
node	I-Cancer
-	I-Cancer
metastatic	I-Cancer
cancer	I-Cancer
.	O

Oral	B-Cancer
squamous	I-Cancer
cell	I-Cancer
carcinoma	I-Cancer
(	O
OSCC	B-Cancer
)	O
often	O
metastasizes	O
to	O
the	O
lymph	B-Multi-tissue_structure
nodes	I-Multi-tissue_structure
,	O
and	O
these	O
enzymes	O
may	O
be	O
significant	O
in	O
the	O
survival	O
of	O
patients	O
with	O
this	O
disease	O
.	O

This	O
study	O
investigated	O
the	O
expression	O
of	O
TS	O
and	O
DPD	O
in	O
cervical	B-Cancer
lymph	I-Cancer
node	I-Cancer
metastases	I-Cancer
and	O
its	O
relationship	O
with	O
primary	B-Cancer
OSCC	I-Cancer
,	O
as	O
well	O
as	O
the	O
interaction	O
between	O
these	O
enzymes	O
and	O
Kangai	O
1	O
(	O
KAI1	O
/	O
CD82	O
)	O
which	O
is	O
a	O
metastasis	O
suppressor	O
protein	O
.	O

Surgical	B-Cancer
specimens	I-Cancer
from	O
20	O
cases	O
of	O
OSCC	B-Cancer
with	O
lymph	B-Multi-tissue_structure
node	I-Multi-tissue_structure
metastasis	O
,	O
20	O
cases	O
of	O
OSCC	B-Cancer
without	O
lymph	B-Multi-tissue_structure
node	I-Multi-tissue_structure
metastasis	O
,	O
and	O
10	O
cases	O
of	O
normal	O
mucosa	B-Multi-tissue_structure
were	O
examined	O
by	O
immunohistochemistry	O
.	O

The	O
relationship	O
between	O
TS	O
and	O
DPD	O
expression	O
and	O
clinicopathological	O
data	O
was	O
analyzed	O
.	O

TS	O
and	O
DPD	O
proteins	O
were	O
overexpressed	O
in	O
primary	B-Cancer
OSCC	I-Cancer
compared	O
to	O
that	O
in	O
normal	O
mucosa	B-Multi-tissue_structure
.	O

TS	O
expression	O
of	O
the	O
primary	B-Cell
oral	I-Cell
cancer	I-Cell
cells	I-Cell
in	O
the	O
group	O
with	O
lymph	B-Multi-tissue_structure
node	I-Multi-tissue_structure
metastasis	O
was	O
higher	O
than	O
that	O
of	O
those	O
without	O
.	O

DPD	O
expression	O
did	O
not	O
significantly	O
correlate	O
with	O
the	O
occurrence	O
of	O
lymph	B-Multi-tissue_structure
node	I-Multi-tissue_structure
metastasis	O
,	O
nor	O
was	O
it	O
different	O
between	O
primary	B-Cell
oral	I-Cell
cancer	I-Cell
cells	I-Cell
and	O
cervical	B-Cancer
metastases	I-Cancer
.	O

CD82	O
expression	O
was	O
significantly	O
reduced	O
in	O
lymph	B-Cancer
node	I-Cancer
metastases	I-Cancer
.	O

These	O
findings	O
indicate	O
that	O
TS	O
and	O
CD82	O
may	O
be	O
of	O
great	O
value	O
in	O
assessing	O
lymph	B-Multi-tissue_structure
node	I-Multi-tissue_structure
metastasis	O
of	O
OSCC	B-Cancer
,	O
and	O
could	O
be	O
taken	O
as	O
new	O
targets	O
for	O
therapy	O
of	O
metastatic	B-Cancer
OSCC	I-Cancer
.	O

